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Introduction
In 2008 the World Allergy Organization (WAO) verified
that the existing guidelines on CMA were usually
national position papers reflecting local views and
needs, with flexible, sometimes evidence-based, strate-
gies [1-4]. Then, a global guideline for IgE-mediated
CMA from diagnosis to treatment was developed using
the GRADE approach [5]. We review here the first steps
of Diagnosis and Rationale for Action Against Cow’s
Milk Allergy (DRACMA) together with the changes in
diagnostic and therapeutic behavior generated by the
new guideline.
How GRADE methodology impact on food allergy
guidelines
Challenges with the guideline development process
include difficulties in synthesizing evidence on diagnos-
tic tests and therapeutic indications, reconciliation of
information obtained through different statistical meth-
ods, transparency in evaluation of diagnostic and thera-
peutic tools, adherence to the clinical questions to
which a physician is confronted in real-life [6].
In order to meet these needs, two panels were consti-
tuted in DRACMA: a clinical panel and a methodologi-
cal GRADE revision panel [7]. Three systematic reviews
addressing the clinical questions were developed by the
GRADE revision panel: 1-diagnosis, 2-use of substitute
formulas and 3-immunotherapy for CMA. The GRADE
evidence profiles for the clinical questions were devel-
oped on these systematic reviews. Summaries of evi-
dence were reviewed by the panel members whose
suggestions were incorporated. The quality of the
evidence was classified as “high”, “moderate”, “low “ or
“very low” [6,8-12]. Finally, the DRACMA guideline
panel reviewed the evidence summaries and formulated
“strong” or “conditional and/or weak” recommendations.
The statements on the underlying values, preferences
and remarks are integral parts of the recommendations,
and serve to facilitate their accurate interpretation.
DRACMA implementation
DRACMA was first introduced at the 2009 Buenos Aires
World Allergy Congress and in a dedicated Meeting in
Milan in February 2010 [13]. After the first publication
in WAO Journal in April 2010, DRACMA was repli-
cated in an indexed journal [14]. The worldwide situa-
tion in diagnosis and treatment of CMA before
DRACMA was described in a round table at the Milan
Meeting [15]. The subsequently published NIAID guide-
lines [16] widely referred to DRACMA, now cited by
dozens. Of note, the method used has been indicated as
an example of transparency in the development of
guidelines and it has become a cornerstone for GRADE
methodology [7,8,17-19]. A DRACMA implementation
committee has been appointed at WAO in order to
favour the diffusion of the guideline. Under its auspices,
aG L O R I AM o d u l eo nD R A C M Ai sb e i n gd e v e l o p e d ,
national translations are being prepared and a dedicated
page on WAO website is in preparation. From this,
mobile and I-Pad applications developed by a volunteer
copyrighted to WAO will be freely available.
CMA diagnosis
The DRACMA guidelines provide indications on CMA
diagnosis using traditional sensitization tests (SPT and
specific IgE determination) vs. the gold standard test
(OFC). This allows personalized decision making proce-
dures tailored to the single patient’s medical history. As
an example, the diagnostic procedure will be different
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any medium, provided the original work is properly cited.for a child with a recent episode of anaphylaxis and for
a child with atopic eczema possibly triggered by cow’s
milk. The clinical history drives the risk assessment
through an estimate of the pretest probability of CMA.
Pretest probability can be low, average (most cases) or
high. The DRACMA guidelines always recommend OFC
for diagnosing CMA as a strong recommendation to
avoid:
- the risk of anaphylactic reactions at home in false
negative sensitization tests,
- unnecessary treatment for false positive cases
- inappropriate resource utilization.
However, many reasons (availability of medical and
nursing staff, hospitals resources, ability of families to
reach reference centers, etc.) may make difficult per-
forming an OFC at the outset. Thus, in selected cases,
using a pretest probability estimate can offer an almost
certain diagnosis simply by performing an SPT and/or
specific IgE determination. The diagnosis would be
“almost” certain because, as in any decision-making
path, there is a small chance of false results. The guide-
lines indicate the price to pay to avoid performing OFC
in all cases and keep it only for selected doubtful cases.
The decision to use OFC in all cases (recommendation
1.1 and 2.1) or to recur to sensitization tests in some
cases (recommendations 1.2, 1.3, 1.4, 2.2, 2.3, 2.4, 3 and
4) [14] should be taken at local level. Four simple
patterns describe these decision processes (Figures 1, 2,
3 and 4). After a scientific review of all the papers avail-
able in the literature via the GRADE method, the
DRACMA guidelines identified the cut off values for
SPT and specific IgE determination results as 3 mm for
wheal diameter in the SPT and 0.35 IU/L specific IgE to
cow’s milk using the CAP-RAST or FEIA method.
How DRACMA changes diagnostic attitudes in CMA?
The DRACMA recommendations substantially modify
the current practice in diagnosing CMA. Per their dic-
tate, the diagnostic OFC performed under the supervi-
sion of a specialist remain the best diagnostic strategy,
to be performed whenever available. This is so evident
that in case OFC is performed out of a research setting,
sensitization tests may not be necessary (recommenda-
tion 1.1). This is counterintuitive for pediatric allergists,
as correct diagnosis of CMA, starting with a suspicion
and ending with the OFC, traditionally passes through
sensitization tests including SPT, atopy patch tests, and
specific IgE determination. Despite the recommenda-
tions, it is current practice that these tests base clinical
decisions. Thus, very often OFC is not part of the diag-
nostic workup and is only indicated after an elimination
period of a few months or upon a specialist’sa d v i c ei n
more severe cases. This exposes whole populations to
overdiagnosis of CMA and to excessive use of elimina-
tion diets [20,21]. However, there are whole regions in
the world and even whole States in the USA where
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Figure 1 In settings where OFC is not considered a requirement, should skin prick tests be used for the diagnosis of IgE-mediated
cow’s milk allergy?.
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Figure 2 In settings where OFC is not considered a requirement, should cow’s milk-specific immunoglobulin E test be used for the
diagnosis of IgE-mediated cow’s milk allergy?.
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Figure 3 In settings where OFC is not considered a requirement, should in vitro specific IgE determination be used for the diagnosis
of CMA in patients suspected of CMA and a positive result of a skin prick test?.
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[15]. In this case, DRACMA recommendations indicate
that challenge may not be necessary in many cases.
OFCs remain necessary in all cases of high uncertainty.
This is also a revolutionary step in CMA diagnosis. The
search for a replacement tests has been very active in
the past years, a sort of philosopher’s stone to avoid
OFC whose practice is considered risky, resource- and
time-consuming [22]. Specific IgE cut-off points, SPT dia-
meters and/or APT have been proposed as replacement
tests. In DRACMA, the limits of these diagnostic prac-
tices are clearly indicated and their possible use is re-
evaluated. Atopy patch test is not considered useful in
the diagnosis of IgE-mediated CMA and molecular diag-
nosis may be useful, but further data are necessary [23].
Treatment with CMA replacement formulas
In its therapeutic guidelines DRACMA recommended a
milk-free diet for cases of IgE-mediated CMA and the
use of appropriate alternative formulas up to at least 2
years of age to meet the nutritional needs of these very
young children (Table 1). The complete recommenda-
tion set is available at http://www.worldallergy.org/publi-
cations/WAO_DRACMA_guidelines.pdf. According to
these recommendations, when a substitute formula is
needed a milk-based extensively hydrolyzed formula
(eHF) is the first choice except in case of anaphylaxis or
eosinophilic esophagitis, where AAF is recommended.
eHFs should be tested on an outpatient basis before
being used at home and new formulas should be moni-
tored for adverse reactions when first administered.
eHFs are preferred over soy formulas (SF) to avoid
untoward reactions to soy. Conversely, eHF is preferred
over extensively hydrolyzed rice formula (eHRF) because
more commonly available on the market. Where readily
available as in Italy, eHRF can adequately replace eHF.
Further studies are required to confirm the benefits of
rice protein over SFs. Milks from buffalo, ewe, goat,
camel, mare or donkey, cannot constitute the treatment
of choice for CMA in the developed world. In particular,
goat and ewe milks may expose patients to severe reac-
tions due to cross-reactivity with cow’s milk. Camel and
dromedary milk can be considered as effective substi-
tutes for children over 2 years of age because for their
low protein fraction sequence homology with cow milk.
Mare’s and donkey’s milks can also be considered as
valid substitutes particularly (but not exclusively) in chil-
dren with delayed-onset CMA (e.g. AD). These
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Figure 4 In settings where OFC is not considered a requirement, should in vitro specific IgE determination be used for the diagnosis
of CMA in patients suspected of CMA and a negative result of a skin prick test?.
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approach to the choice of a substitute formula. As an
example, SFe, widely used, are a second-line choice due
to possibility of secondary sensitization and to nutri-
tional drawbacks. In any case, SF cannot be considered
under 6 months of age
Use of OIT in CMA
The DRACMA guidelines recommend that OIT be
administered to patients with IgE-mediated CMA only
within the context of formal clinical research to avoid
serious adverse effects that negatively offset the
increased probability of desensitization to milk. How-
ever, due to the rapidly growing literature, a new meta-
nalysis will be produced shortly.
Conclusion
Pediatric medicine is a science, not an art. In a field tra-
ditionally open to various interpretations, as CMA,
DRACMA guidelines draw a definitive borderline
between diagnostic possibilities, and a clear indication in
t h ec h o i c eo ft h ea p p r o p r i a t e formula. The application
of DRACMA recommendations to the Italian reality
should favour the diffusion of the correct diagnostic
practices in a context very rich of diagnostic facilities
[24] but in need of standardization of the procedures
[25]. If correctly applied, they should also modify the
composition of the special formulae market, avoiding
unnecessary treatments.
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